Oura Targets $15.6 Billion Valuation in Nasdaq IPO Debut

Oura Inc. plans to list on the Nasdaq under the ticker OURA during the week of Sept. 28, offering 50 million shares priced between $40 and $44 for a fully diluted valuation of up to $15.6 billion. The smart ring maker launched its roadshow on Sept. 21, 2026, targeting an initial market capitalization of $12.8 billion to $14.1 billion.

The pitch to investors rests on a financial profile that breaks the hardware mold. For the nine months ended June 30, 2026, Oura's membership software revenue grew about 121% year over year to roughly $240.5 million, while total net revenue advanced about 74% to $1.21 billion. The company posted $60.8 million in net income and around $106.7 million in EBITDA — a rarity among recent IPOs, most of which arrived on public markets with widening operational deficits.

The subscription engine

Hardware makers typically grapple with uneven revenue because customers buy a device once every three or four years, capping lifetime value. Oura attacks that structural problem by pairing titanium rings with a membership priced at $5.99 per month.

The engagement metrics back the model. Oura counts around five million active paid members across 56 geographic markets. Users record a median daily wear time of 23 hours, and daily active users run at roughly 65% of monthly active users. The platform holds an 85% 12-month paid subscriber retention rate.

That engagement drove operating leverage. Gross margin rose to 55% from 51% in the prior-year period.

Big Pharma buys in

The defining catalyst behind institutional demand sits at the intersection of wearables and metabolic medicine. As millions of patients begin GLP-1 treatments for diabetes and weight management, practitioners need continuous physiological data outside clinic visits. Oura introduced software features that track heart rate variability, sleep quality shifts, and lean muscle retention during weight-loss regimens.

Eli Lilly and Company (NYSE: LLY) has indicated interest in buying up to $100 million of common stock in the offering. The pharmaceutical giant already collaborates with Oura to integrate biometric tracking through the LillyDirect digital healthcare channel, giving patients and doctors continuous data on treatment response.

A separate operational partnership with Dexcom Inc. (NASDAQ: DXCM) connects glucose readings from the Stelo sensor directly into Oura's mobile software. Members can see how nutritional spikes affect overnight resting heart rates and daytime recovery scores. These clinical connections shift Oura from a consumer fitness gadget toward a continuous monitoring asset.

What the multiple buys

At the midpoint price of $42 per share, Oura trades at around 9.7x annualized sales on its latest nine-month run rate. Garmin Ltd. (NYSE: GRMN) trades closer to 7.5x sales; Apple Inc. (NASDAQ: AAPL) commands roughly 12x. Institutional backers including Dragoneer Investment Group, which indicated an order of up to $300 million, accept the premium because Oura delivers 74% top-line growth alongside positive net income.

Patents add a defensive moat. Following enforcement proceedings before the U.S. International Trade Commission, Oura secured licensing agreements and recurring royalties from competing smart ring brands, limiting low-cost overseas manufacturers from copying its miniaturized sensor package without paying.

The risks

Ring hardware still generates approximately 80% of total revenue, leaving Oura exposed to cyclical discretionary spending and component supply chain disruptions.

The capital structure deserves scrutiny. Of the 50 million shares offered, existing stockholders are selling 36.5 million, handing venture backers significant early liquidity. Of the estimated $532.6 million in net primary proceeds at the midpoint, roughly $526.4 million covers tax withholding tied to restricted stock unit settlements — leaving limited primary capital for acquisitions or cash reserves.

Investors must also weigh an active consumer class-action lawsuit disclosed in the regulatory paperwork. The litigation challenges the scientific precision and advertising claims of Oura's sleep-tracking technology. An unfavorable outcome could create reputational headwinds or force adjustments to marketing claims.

What to watch

Retail access through brokerages including Robinhood Markets Inc. (NASDAQ: HOOD) could drive active opening volume alongside institutional anchors. Watch where final pricing settles within the $40 to $44 range, and how underwriting syndicates manage early supply.

The long-term test arrives in quarterly earnings: whether subscription growth stays above 120% and gross margin holds near 55% will determine whether Oura's $15.6 billion wager on health intelligence pays off.